Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

Inclusion Criteria: * 19 years or older * HSV-2 (Herpes simplex virus type 2) seropositive as determined by HerpeSelect-2 ELISA * Documented HIV-1 seropositive * Currently receiving HAART for 3 months or longer * CD4 (cluster of differentiation 4) count 350 or greater * Women of child bearing potential must agree to use acceptable contraceptive measures during the entire conduct of the study. Acceptable contraceptive methods include one or more of the following: oral hormonal contraceptives, injectable hormonal contraceptives, transdermal hormonal contraceptives, IUD (intrauterine device), diaphragm or cervical cap. * Willing and able to provide written informed consent, undergo clinical evaluations, and take study drug as directed Exclusion Criteria: * History of symptomatic genital herpes, lesions or symptoms consistent with genital herpes, or recurrent undiagnosed symptoms consistent with genital herpes. * Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir. * Planned open label use of acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, cidofovir, or foscarnet for oral herpes or other herpes viral infections. * Medical history of seizures * Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl * AST (aspartate aminotransferase) or ALT (alanine aminotransferase) over 5 times uper limit of normal * History of thrombotic microangiopathy * For women, pregnancy as confirmed by a urine or serum pregnancy test. * Any other condition which, in the opinion of the principal investigator, may compromise the subject's ability to follow study procedures and complete the study. * Participants with active bacterial STDs (sexually transmitted diseases) may be treated and be eligible for enrollment 14 days after STD therapy is discontinued and symptoms have resolved.